Evidence map›Paper›PMID 25025235›Full record

ArticlePLoS medicine2014

The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model.

Henrik Salje, Jason R Andrews, Sarang Deo, Srinath Satyanarayana, Amanda Y Sun, Madhukar Pai, David W Dowdy

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03044158 (GeneXpert Performance Evaluation for Linkage to Tuberculosis Care), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03044158 nacompletednot on this mapstarted 2018, after this paper: background citation

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care: The XPEL-TB Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2018 to 2022Enrolled10,644ConditionsTuberculosis, Pulmonary, Rifampicin Resistant TuberculosisArmsGeneXpert I, Process re-design, Performance Feedback
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Closing gaps in the tuberculosis care cascade: an action-oriented research agenda.Journal of clinical tuberculosis and other mycobacterial diseases · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2016
    Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Henrik SaljeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Jason R AndrewsDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Sarang DeoIndian School of Business, Hyderabad, India.
Srinath SatyanarayanaDepartment of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada; McGill International TB Centre, McGill University Health Centre, Montreal, Quebec, Canada.
Amanda Y SunJohns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
Madhukar PaiDepartment of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada; McGill International TB Centre, McGill University Health Centre, Montreal, Quebec, Canada; Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada.
David W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, United States of America.
Johns Hopkins University · USIndian School of Business · INMassachusetts General Hospital · USMcGill University · CAMcGill University Health Centre · CA

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
CIHR MOP 123291FIC NIH HHS D43 TW010540
6 · The paper itself

Abstract

backgroundIndia has announced a goal of universal access to quality tuberculosis (TB) diagnosis and treatment. A number of novel diagnostics could help meet this important goal. The rollout of one such diagnostic, Xpert MTB/RIF (Xpert) is being considered, but if Xpert is used mainly for people with HIV or high risk of multidrug-resistant TB (MDR-TB) in the public sector, population-level impact may be limited. METHODS AND

findingsWe developed a model of TB transmission, care-seeking behavior, and diagnostic/treatment practices in India and explored the impact of six different rollout strategies. Providing Xpert to 40% of public-sector patients with HIV or prior TB treatment (similar to current national strategy) reduced TB incidence by 0.2% (95% uncertainty range [UR]: -1.4%, 1.7%) and MDR-TB incidence by 2.4% (95% UR: -5.2%, 9.1%) relative to existing practice but required 2,500 additional MDR-TB treatments and 60 four-module GeneXpert systems at maximum capacity. Further including 20% of unselected symptomatic individuals in the public sector required 700 systems and reduced incidence by 2.1% (95% UR: 0.5%, 3.9%); a similar approach involving qualified private providers (providers who have received at least some training in allopathic or non-allopathic medicine) reduced incidence by 6.0% (95% UR: 3.9%, 7.9%) with similar resource outlay, but only if high treatment success was assured. Engaging 20% of all private-sector providers (qualified and informal [providers with no formal medical training]) had the greatest impact (14.1% reduction, 95% UR: 10.6%, 16.9%), but required >2,200 systems and reliable treatment referral. Improving referrals from informal providers for smear-based diagnosis in the public sector (without Xpert rollout) had substantially greater impact (6.3% reduction) than Xpert scale-up within the public sector. These findings are subject to substantial uncertainty regarding private-sector treatment patterns, patient care-seeking behavior, symptoms, and infectiousness over time; these uncertainties should be addressed by future research.

conclusionsThe impact of new diagnostics for TB control in India depends on implementation within the complex, fragmented health-care system. Transformative strategies will require private/informal-sector engagement, adequate referral systems, improved treatment quality, and substantial resources. Please see later in the article for the Editors' Summary.

Indexed as

HumansIndiaModels, TheoreticalTuberculosis, Multidrug-ResistantTuberculosis, Pulmonary

Identifiers

PMID25025235
PMCPMC4098913
OpenAlexW2135358044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.